Keywords
SARS-CoV-2
COVID-19
Autoimmunity
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To correlate neurological manifestations that fit the diagnoses of Guillain-Barré syndrome to SARS-CoV-2 infection. Bibliographic review: SARS-CoV-2 can induce direct and indirect damage, due to the immune response, in structures, especially the PNS, causing tissue damage (consequently, neural damage), inflammation and even autoimmunity. The extensive release of inflammatory cytokines in SARS-CoV-2 infection may be part of the immunopathology behind the occurrence of GBS after Covid-19 infection. The molecular mimicry mechanism is described as the most likely in the genesis of GBS from Covid-19. This is because antibodies produced against glycoproteins present in the structure of SARS-CoV-2 can damage the host's peripheral nerves due to the similarity with native proteins. As a consequence, there is formation of self-reactive B and T cells. Thus, the antibodies formed cross-react and end up damaging the PNS cells. Final considerations: The inflammatory reaction and immune reaction of SARS-CoV-2 can trigger autoimmune syndromes such as GBS.
References
ABRAMS RMC, et al. Severe rapidly progressive Guillain-Barré syndrome in the setting of acute Covid-19 disease. J NeuroVirol, 2020; 26(5): 797–799.
ABU-RUMEILEH S, et al. Guillain-Barré syndrome spectrum associated with Covid-19: an up-to-date systematic review of 73 cases. J Neurol, 2021; 268(4): 1133-1170.
ATAKLA HG, et al. Acute Guillain-Barré polyradiculoneuritis indicative of Covid-19 infection: a case report. Pan Afr Med J, 2020; 35(Suppl 2): 150.
BIGAUT K, et al. Guillain-Barré syndrome related to SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm. 2020; 7(5): e785.
BRASIL. Ministério da Saúde. CONITEC. 2021. Disponível em: http://conitec.gov.br/images/Protocolos/Publicacoes_MS/20210713_Publicacao_Guillian_Barre.pdf. Acessado em: 2 de junho de 2022.
CARESS JB, et al. Covid‐19–associated Guillain‐Barré syndrome: The early pandemic experience. Muscle & nerve, 2020; 62(4): 485-491.
CHAKRABORTY N, KUMAR H. Intravenous Immunoglobulin may Reverse Multisystem Inflammation in Covid-19 Pneumonitis and Guillain-Barré Syndrome. Indian J Crit Care Med, 2020; 24(12): 1264-1268.
CHAKRABORTY U, et al. Covid-19 associated Guillain-Barré syndrome: A series of a relatively uncommon neurological complication. Diabetes Metab Syndr, 2021; 15(6): 102326.
DUFOUR C. GM1 ganglioside antibody and Covid-19 related Guillain Barre Syndrome - A case report, systemic review and implication for vaccine development. Brain Behav Immun Health, 2021; 12: 100203.
ELZOUKI AN, et al. Covid-19 infection presented as Guillain-Barre Syndrome: Report of two new cases and review of 116 reported cases and case series. Travel Med Infect Dis, 2021; 44: 102169.
GARCIA JJ, et al. Intravenous immunoglobulin in Covid-19 associated Guillain-Barré syndrome in pregnancy. BMJ Case Rep, 2021; 14(5): e242365.
GHANNAM M, et al. Neurological involvement of coronavirus disease 2019: a systematic review. J Neurol, 2020; 267(11): 3135-3153.
GOUDARZI S, et al. Treatment Options for Covid-19-Related Guillain-Barré Syndrome: A Systematic Review of Literature. Neurologist, 2021; 26(5): 196-224.
GUPTA A, et al. Extrapulmonary manifestations of Covid-19. Nat Med, 2020; 26(7): 1017-1032.
GUPTA S, et al. Treatment related fluctuation and response to intravenous immunoglobulin therapy in post Covid-19 Guillain-Barre syndrome. Diabetes Metab Syndr, 2021; 15(5): 102246.
JHA NK, et al. Evidence of Coronavirus (CoV) Pathogenesis and Emerging Pathogen SARS-CoV-2 in the Nervous System: A Review on Neurological Impairments and Manifestations. J Mol Neurosci, 2021; 71(11): 2192-2209.
KOIKE H, KATSUNO M. Emerging infectious diseases, vaccines and Guillain-Barré syndrome. Clin Exp Neuroimmunol, 2021; 10.1111/cen3.12644.
LANTOS JE, et al. Covid-19-Associated Miller Fisher Syndrome: MRI Findings. AJNR Am J Neuroradiol, 2020; 41(7): 1184-1186.
LEHMANN HC, et al. Neuromuscular complications of SARS-CoV-2 infections-Part 1: peripheral nerves. Nervenarzt, 2021; 92(6): 540-547.
LI YC, et al. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of Covid-19 patients. J Med Virol, 2020; 92(6): 552-555.
LIU Y, et al. Covid-19 and autoimmune diseases. Curr Opin Rheumatol, 2021; 33(2): 155-162.
LUCCHESE G, FLÖEL A. SARS-CoV-2 and Guillain-Barré syndrome: molecular mimicry with human heat shock proteins as potential pathogenic mechanism. Cell Stress Chaperones, 2020; 25(5): 731-735.
MACKENZIE N, et al. Concomitant Guillain-Barre syndrome with Covid-19: a case report. BMC Neurol, 2021; 21(1): 135.
MEDEIROS KS, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection: a scoping review. Rev Assoc Med Bras, 2021; 67(2): 318-334.
MEHTA SK, SUNDER A. Getting paralysed after Covid: Guillain-Barre syndrome. J Family Med Prim Care, 2021; 10(7): 2706-2708.
MOHAMMADI S, et al. Understanding the Immunologic Characteristics of Neurologic Manifestations of SARS-CoV-2 and Potential Immunological Mechanisms. Mol Neurobiol, 2020; 57(12): 5263-5275.
MOHAMMADI SM, et al. Guillain-Barré/Miller Fisher overlap syndrome in a patient after coronavirus disease-2019 infection: a case report. J Med Case Rep, 2022; 16(1): 63.
MONTIEL-JAROLÍN DE, et al. Síndrome de Guillain Barré asociado a la infección por el SARS-CoV-2, en paciente con diagnóstico diferencial por dengue. Revista de Salud Publica del Paraguay, 2021; 11(1): 112-116.
PADRÓN-GONZÁLEZ AA, DORTA-CONTRERAS AJ. Patogenia de las manifestaciones neurológicas asociadas al SARS-CoV-2. Revista Cubana de Investigaciones Biomédicas, 2020; 39(3): e868.
RAJDEV K, et al. A Case of Guillain-Barré Syndrome Associated With Covid-19. J Investig Med High Impact Case Rep, 2020; 8: 2324709620961198.
RIGO D, et al. Síndrome de Guillain Barré: perfil clínico epidemiológico e assistência de enfermagem. Enf. Global, 2019; 19(1): 346-389.
SEGURA-CHÁVEZ D, et al. Síndrome de Guillain Barré e infección por SARS-CoV-2: reporte de dos casos en Perú. Rev Neuropsiquiatr, 2021; 84(1): 58-63.
SHAH S, et al. Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment. Rheumatol Int, 2020; 40(10): 1539-1554.
TEKIN AB, et al. Guillain Barre Syndrome following delivery in a pregnant woman infected with SARS-CoV-2. J Clin Neurosci, 2021; 86: 190-192.
YANG X, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med, 2020; 8(5): 475-481.
ZITO A, et al. Covid-19 and Guillain-Barré Syndrome: A Case Report and Review of Literature. Front Neurol, 2020; 11: 909.
ZUBAIR AS, et al. Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. JAMA Neurol, 2020; 77(8): 1018-1027.